Skip to content
    Surveyor Capital logo

    Surveyor Capital

    Chicago, Illinois, United StatesFounded 2008
    www.surveyor-capital.comLinkedIn
    Biotech & Life SciencesHealthcare

    Surveyor Capital, a fundamental equities strategy of Citadel, focuses on deep fundamental research across diverse sectors including Consumer, Financials, Healthcare, Industrials, Energy & Natural Resources, and Technology, Media & Telecom. Their strategy involves developing independent views on companies, leveraging a market-neutral risk framework to minimize broad market exposures, and also acting as a seeding platform for long/short equity hedge fund managers.

    93% of their portfolio is in Biotech & Life Sciences. Deal activity decreased year-over-year (4 deals in the last 12 months vs 6 prior). Their most common stage is series-b (41% of deals). Average disclosed round size is $122.8M (across 29 rounds with reported amounts).

    Find people at Surveyor Capital on Goldilocks AI

    Portfolio

    29

    Fund Size

    —

    Top Stage

    Series B

    Last 12 Mo

    4

    Portfolio Breakdown

    Stage Distribution

    Sector Distribution

    Investment Activity

    DealsAvg Round Size

    Portfolio

    29 investments
    CompanyRoundAmountDate
    SSoley TherapeuticsSeries C$200MJan 2026
    Triana Biomedicines logoTriana BiomedicinesSeries B$120MDec 2025
    SSolve Therapeutics, Inc.Series D$120MNov 2025
    Adcytherix logoAdcytherixSeries A$105MOct 2025
    DDBV Technologies S.A.Unknown$306.9MMar 2025
    Arbor Biotechnologies Inc logoArbor Biotechnologies IncSeries C$73.9MMar 2025
    35Pharma Inc. logo35Pharma Inc.Series C$53MNov 2024
    Adcendo ApS logoAdcendo ApSSeries B$135MNov 2024
    Outpace Bio logoOutpace BioSeries B$144MAug 2024
    BridgeBio Oncology Therapeutics (BBOT) logoBridgeBio Oncology Therapeutics (BBOT)Growth$200MMay 2024
    Remix Therapeutics logoRemix TherapeuticsSeries C$60MJan 2024
    Avalyn Pharma Inc. logoAvalyn Pharma Inc.Series C$175MSep 2023
    CCompass PathwaysUnknown$285MAug 2023
    Quanta Therapeutics logoQuanta TherapeuticsSeries D$50.7MMay 2023
    Plexium, Inc. logoPlexium, Inc.Growth$102MFeb 2022
    Arkuda Therapeutics logoArkuda TherapeuticsSeries B$64MFeb 2022
    ImmPACT Bio USA, Inc. logoImmPACT Bio USA, Inc.Series B$111MJan 2022
    Arbor Biotechnologies Inc logoArbor Biotechnologies IncSeries B$215MNov 2021
    Obsidian Therapeutics logoObsidian TherapeuticsSeries B$115MSep 2021
    GGennao BioSeries A$40MMay 2021
    DTx Pharma logoDTx PharmaSeries B$100MMar 2021
    Vera Therapeutics logoVera TherapeuticsSeries C$80MJan 2021
    Neuron23 logoNeuron23Series B$113.5MDec 2020
    Enliven Therapeutics logoEnliven TherapeuticsSeries B$85MDec 2020
    BBioShin LimitedSeries A$60MSep 2020
    Page 1 of 2

    Top Co-Investors

    Logos Capital10 shared
    RA Capital Management9 shared
    Janus Henderson Investors7 shared
    Cormorant Asset Management5 shared
    Pivotal bioVenture Partners5 shared
    Sofinnova Partners4 shared
    Atlas Venture4 shared
    Deep Track Capital4 shared
    Vivo Capital4 shared
    Alexandria Venture Investments4 shared
    OrbiMed3 shared
    Pfizer Ventures3 shared
    Ally Bridge Group3 shared
    ARCH Venture Partners3 shared
    Samsara BioCapital3 shared
    Rock Springs Capital3 shared
    Redmile Group3 shared
    Avidity Partners2 shared
    Longitude Capital2 shared
    Eli Lilly and Company2 shared

    Last updated: 16 April 2026